Breaking Finance News

Summit Therapeutics PLC (LON:SUMM) has been reiterated to Corporate in a statement by N+1 Singer earlier today.

Yesterday Summit Therapeutics PLC (LON:SUMM) traded -11.66% lower at 137.50GBX. SUMM’s 50-day average is 100.75GBX and its 200-day moving average is 105.23GBX. With the last closing price up 25.93% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Trade Volume was up over the average, with 91,871 shares of SUMM changing hands over the typical 44,113

N+1 Singer has reiterated Summit Therapeutics PLC (LON:SUMM) to Corporate in a statement released on 9/27/2016.

Recent Performance Chart

Summit Therapeutics PLC (LON:SUMM)

Summit Therapeutics PLC has 52 week low of 82.66GBX and a 52 week high of 159.00GBX and has a market capitalization of 0 GBX.

More About Summit Therapeutics PLC (LON:SUMM)

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *